Oruka Therapeutics annual shares outstanding
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oruka Therapeutics Shares Outstanding History (ORKA)
Oruka Therapeutics reported 48.7M shares outstanding at the end of fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 48.7M | 11.3M | +30.13% |
| 2024 | 2024-12-31 | 37.4M | 22.9M | +158.19% |
| 2023 | 2023-12-31 | 14.5M | 91,000 | +0.63% |
| 2022 | 2022-12-31 | 14.4M | 0 | 0.00% |
| 2021 | 2021-12-31 | 14.4M | 4.9M | +50.92% |
| 2020 | 2020-12-31 | 9.5M | 8.0M | +498.98% |
| 2019 | 2019-12-31 | 1.6M | 820,512 | +106.07% |
| 2018 | 2018-12-31 | 773,558 | 119,387.889 | +18.25% |
| 2017 | 2017-12-31 | 654,170.111 | 149,594.222 | +29.65% |
| 2016 | 2016-12-31 | 504,575.889 | 1,730.5 | +0.34% |
| 2015 | 2015-12-31 | 502,845.389 | 334,984.389 | +199.56% |
| 2014 | 2014-12-31 | 167,861 | 43,372.413 | +34.84% |
| 2013 | 2013-12-31 | 124,488.587 | 103,374.976 | +489.61% |
| 2012 | 2012-12-31 | 21,113.611 | 4,998.532 | +31.02% |
| 2011 | 2011-12-31 | 16,115.079 | 4,429.187 | +37.90% |
| 2010 | 2010-12-31 | 11,685.893 | — | — |
Oruka Therapeutics quarterly shares outstanding
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 61.1M | 23.6M | +63.07% |
| Q1 2026 | 2026-03-31 | 50.2M | 12.7M | +33.99% |
| Q4 2025 | 2025-12-31 | 48.7M | 11.3M | +30.13% |
| Q3 2025 | 2025-09-30 | 48.4M | 13.4M | +38.25% |
| Q2 2025 | 2025-06-30 | 37.5M | 22.9M | +158.15% |
| Q1 2025 | 2025-03-31 | 37.4M | 22.9M | +158.19% |
| Q4 2024 | 2024-12-31 | 37.4M | 22.9M | +158.19% |
| Q3 2024 | 2024-09-30 | 35.0M | 20.6M | +142.87% |
| Q2 2024 | 2024-06-30 | 14.5M | 97,000 | +0.67% |
| Q1 2024 | 2024-03-31 | 14.5M | 91,000 | +0.63% |
| Q4 2023 | 2023-12-31 | 14.5M | 91,000 | +0.63% |
| Q3 2023 | 2023-09-30 | 14.4M | 0 | 0.00% |
| Q2 2023 | 2023-06-30 | 14.4M | 0 | 0.00% |
| Q1 2023 | 2023-03-31 | 14.4M | 0 | 0.00% |
| Q4 2022 | 2022-12-31 | 14.4M | 0 | 0.00% |
| Q3 2022 | 2022-09-30 | 14.4M | 0 | 0.00% |
| Q2 2022 | 2022-06-30 | 14.4M | 0 | 0.00% |
| Q1 2022 | 2022-03-31 | 14.4M | 0 | 0.00% |
| Q4 2021 | 2021-12-31 | 14.4M | 4.9M | +50.92% |
| Q3 2021 | 2021-09-30 | 14.4M | 5.1M | +55.19% |
| Q2 2021 | 2021-06-30 | 14.4M | 12.1M | +535.49% |
| Q1 2021 | 2021-03-31 | 14.4M | 12.8M | +803.98% |
| Q4 2020 | 2020-12-31 | 9.5M | 8.0M | +498.98% |
| Q3 2020 | 2020-09-30 | 9.3M | 7.7M | +482.51% |
| Q2 2020 | 2020-06-30 | 2.3M | 812,014 | +55.79% |
| Q1 2020 | 2020-03-31 | 1.6M | 495,257 | +45.07% |
| Q4 2019 | 2019-12-31 | 1.6M | 820,512 | +106.07% |
| Q3 2019 | 2019-09-30 | 1.6M | 820,524.167 | +106.07% |
| Q2 2019 | 2019-06-30 | 1.5M | 682,010.167 | +88.17% |
| Q1 2019 | 2019-03-31 | 1.1M | 325,795.222 | +42.15% |
| Q4 2018 | 2018-12-31 | 773,558 | 119,387.889 | +18.25% |
| Q3 2018 | 2018-09-30 | 773,545.833 | 120,726.722 | +18.49% |
| Q2 2018 | 2018-06-30 | 773,545.833 | 211,513.278 | +37.63% |
| Q1 2018 | 2018-03-31 | 773,017.778 | 263,414 | +51.69% |
| Q4 2017 | 2017-12-31 | 654,170.111 | 149,594.222 | +29.65% |
| Q3 2017 | 2017-09-30 | 652,819.111 | 148,335.611 | +29.40% |
| Q2 2017 | 2017-06-30 | 562,032.556 | 58,346.556 | +11.58% |
| Q1 2017 | 2017-03-31 | 509,603.778 | 6,456.722 | +1.28% |
| Q4 2016 | 2016-12-31 | 504,575.889 | 1,730.5 | +0.34% |
| Q3 2016 | 2016-09-30 | 504,483.5 | 1,717.444 | +0.34% |
| Q2 2016 | 2016-06-30 | 503,686 | 1,940.048 | +0.39% |
| Q1 2016 | 2016-03-31 | 503,147.056 | 334,905.698 | +199.06% |
| Q4 2015 | 2015-12-31 | 502,845.389 | 334,984.389 | +199.56% |
| Q3 2015 | 2015-09-30 | 502,766.056 | 334,984.421 | +199.65% |
| Q2 2015 | 2015-06-30 | 501,745.952 | 334,993.452 | +200.89% |
| Q1 2015 | 2015-03-31 | 168,241.357 | 1,561.278 | +0.94% |
| Q4 2014 | 2014-12-31 | 167,861 | 43,372.413 | +34.84% |
| Q3 2014 | 2014-09-30 | 167,781.635 | 63,056.54 | +60.21% |
| Q2 2014 | 2014-06-30 | 166,752.5 | 86,624.23 | +108.11% |
| Q1 2014 | 2014-03-31 | 166,680.079 | 141,397.841 | +559.28% |
| Q4 2013 | 2013-12-31 | 124,488.587 | 103,374.976 | +489.61% |
| Q3 2013 | 2013-09-30 | 104,725.095 | 85,387.003 | +441.55% |
| Q2 2013 | 2013-06-30 | 80,128.27 | 64,013.192 | +397.23% |
| Q1 2013 | 2013-03-31 | 25,282.238 | 9,167.16 | +56.89% |
| Q4 2012 | 2012-12-31 | 21,113.611 | 4,998.532 | +31.02% |
| Q3 2012 | 2012-09-30 | 19,338.093 | 5,427.599 | +39.02% |
| Q2 2012 | 2012-06-30 | 16,115.078 | 2,205.413 | +15.86% |
| Q1 2012 | 2012-03-31 | 16,115.078 | — | — |
| Q4 2011 | 2011-12-31 | 16,115.079 | 4,429.187 | +37.90% |
| Q3 2011 | 2011-09-30 | 13,910.493 | — | — |
| Q2 2011 | 2011-06-30 | 13,909.665 | — | — |
| Q4 2010 | 2010-12-31 | 11,685.893 | — | — |
Oruka Therapeutics shares outstanding trends
Over the last five fiscal years, Oruka Therapeutics's shares outstanding moved from 9.5M to 48.7M, a change of 39.2M. The latest reported quarter, Q2 2026, shows 61.1M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗Community posts
Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipien ...
